UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

The Lancet (British edition), 2013-02, Vol.381 (9865), p.468-475

2013

Volltextzugriff (PDF)

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B

Hepatology (Baltimore, Md.), 2014-02, Vol.59 (2), p.434-442

2014

Volltextzugriff (PDF)

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

Digestive diseases and sciences, 2015-05, Vol.60 (5), p.1457-1464

2015

Volltextzugriff (PDF)

Development of a sensitive, multi-assay platform to monitor low levels of HBV DNA and pgRNA in patients with chronic hepatitis B virus infection

Journal of virological methods, 2023-01, Vol.311, p.114640-114640, Article 114640

2023

Volltextzugriff (PDF)

Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro

Antiviral research, 2017-03, Vol.139, p.25-31

2017

Volltextzugriff (PDF)

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

The lancet. Gastroenterology & hepatology, 2016-11, Vol.1 (3), p.185-195

2016

Volltextzugriff (PDF)

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection

Antimicrobial agents and chemotherapy, 2018-10, Vol.62 (10)

2018

Volltextzugriff (PDF)

Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients

Journal of hepatology, 2014-04, Vol.60 (4), p.715-722

2014

Volltextzugriff (PDF)

Development of an HIV‐1 integrase genotyping assay for HIV‐1 subtype AE

Journal of medical virology, 2019-05, Vol.91 (5), p.890-893

2019

Volltextzugriff (PDF)

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

Hepatology (Baltimore, Md.), 2013-08, Vol.58 (2), p.505-513

2013

Volltextzugriff (PDF)

Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study

Journal of hepatology, 2017-01, Vol.66 (1), p.11-18

2017

Volltextzugriff (PDF)

Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction

BMC bioinformatics, 2016-08, Vol.17 Suppl 8 (Suppl 8), p.280-280, Article 280

2016

Volltextzugriff (PDF)

Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations

PloS one, 2017-02, Vol.12 (2), p.e0169948

2017

Volltextzugriff (PDF)

HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D

Liver international, 2014-08, Vol.34 (7), p.1025-1032

2014

Volltextzugriff (PDF)

No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-Resistant Chronic Hepatitis B

Clinical gastroenterology and hepatology, 2014-12, Vol.12 (12), p.2106-2112.e1

2014

Volltextzugriff (PDF)

Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment

Journal of virological methods, 2017-11, Vol.249, p.189-193

2017

Volltextzugriff (PDF)

Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure

Liver international, 2019-11, Vol.39 (11), p.2066-2076

2019

Volltextzugriff (PDF)

Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate

Journal of hepatology, 2015-05, Vol.62 (5), p.1033-1039

2015

Volltextzugriff (PDF)

Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B

Digestive diseases and sciences, 2015-01, Vol.60 (1), p.260-268

2015

Volltextzugriff (PDF)

Multiple V1/V2 env Variants Are Frequently Present during Primary Infection with Human Immunodeficiency Virus Type 1

Journal of Virology, 2004-10, Vol.78 (20), p.11208-11218

2004

Volltextzugriff (PDF)

Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF

Journal of medical virology, 2014-09, Vol.86 (9), p.1473-1481

2014

Volltextzugriff (PDF)

ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents covalently closed circular DNA formation by disruption of incoming capsids

Journal of hepatology, 2022-07, Vol.77, p.S844-S845

2022

Volltextzugriff (PDF)

Virologic Failure in Therapy-Naïve Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope

Antimicrobial Agents and Chemotherapy, 2009-03, Vol.53 (3), p.1124-1131

2009

Volltextzugriff (PDF)

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry

AIDS research and human retroviruses, 2010-01, Vol.26 (1), p.13

2010

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(57)

Sprache

Englisch
(57)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(38)
Science & Technology
(38)
Life Sciences & Biomedicine
(36)
Hepatitis B, Chronic - Drug Therapy
(20)
Tenofovir
(19)
Adenine - Analogs & Derivatives
(18)
Gastroenterology & Hepatology
(18)
Female
(16)
Hepatitis B Virus - Genetics
(16)
Hepatitis B
(15)
Male
(15)
Virology
(14)
Hepatitis B Virus
(13)
Adult
(12)
Antiviral Agents
(11)
Biological And Medical Sciences
(11)
Hepatitis
(11)
Infectious Diseases
(11)
Medical Sciences
(11)
Antiviral Agents - Therapeutic Use
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

Development of a sensitive, multi-assay platform to monitor low levels of HBV DNA and pgRNA in patients with chronic hepatitis B virus infection

Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection

Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

Development of an HIV‐1 integrase genotyping assay for HIV‐1 subtype AE

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study

Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction

Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations

HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D

No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-Resistant Chronic Hepatitis B

Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment

Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure

Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate

Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B

Multiple V1/V2 env Variants Are Frequently Present during Primary Infection with Human Immunodeficiency Virus Type 1

Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF

ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents covalently closed circular DNA formation by disruption of incoming capsids

Virologic Failure in Therapy-Naïve Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry

Suchergebnisse filtern